Navigation Links
Anti-cancer drug prevents, reverses cardiovascular damage in mouse model of premature aging disorder
Date:10/6/2008

An experimental anti-cancer drug can prevent -- and even reverse -- potentially fatal cardiovascular damage in a mouse model of progeria, a rare genetic disorder that causes the most dramatic form of human premature aging, National Institutes of Health (NIH) researchers reported today.

In a study published in the Oct. 6 early online edition of the Proceedings of the National Academy of Sciences, a team led by Francis S. Collins, M.D., Ph.D., of the National Human Genome Research Institute (NHGRI), and Elizabeth G. Nabel, M.D., director of the National Heart, Lung and Blood Institute (NHLBI), describes its effort to use transgenic mice to identify and test potential therapies for children with Hutchinson-Gilford progeria syndrome.

There currently are no treatments for progeria, which is estimated to affect about one child in 4 million. At birth, children with progeria appear normal. But soon growth slows, and the children begin to show signs of accelerated aging, such as hair loss, wrinkled skin and loss of body fat. The most lethal damage, however, occurs within the children's major blood vessels. The children develop premature cardiovascular disease, which typically leads to death from heart attack or stroke at about the age of 13.

Building upon its past experiments in cells and mice, the NIH-led team examined the effects of an experimental cancer drug, tipifarnib, in a strain of mice genetically engineered to develop cardiovascular damage similar to that seen in progeria patients. Tipifarnib belongs to a class of drugs known as farnesyltransferase inhibitors (FTIs), which are being tested in people with myeloid leukemia, neurofibromatosis and other conditions. The team had previously found that FTI drugs could reverse structural abnormalities in skin cells taken from progeria patients and grown in the laboratory.

"This approach worked much better than we thought it would. Not only did this drug prevent these mi
'/>"/>

Contact: Geoff Spencer
spencerg@mail.nih.gov
301-402-0911
NIH/National Human Genome Research Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
2. Novel anti-cancer mechanism found in long-lived rodents
3. Gene therapy anti-cancer research featured in Scientific American
4. Drug reverses mental retardation caused by genetic disorder
5. Blood vessel protein reverses macular degeneration, diabetic retinopathy in mice
6. New discoveries from Harvard and Baylor get to the heart of cardiovascular disease
7. Gladstone and Izumi Bio in partnership in regenerative medicine and cardiovascular disease
8. New research shows no link between aromatase inhibitors and cardiovascular problems
9. Genetic variants of USF1 are associated with the increased risk for cardiovascular disease
10. Cell Therapy for Cardiovascular Diseases
11. Medical breakthrough for organ transplants and cardiovascular diseases by Flemish researchers

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...TTE, Ind. - Researchers at Purdue University have ...rve fibers in spinal cord injuries using nano-sphe...after an accident. , The synthetic "copolymer mi...ers in diameter, or roughly 100 times smaller than... have been studying how to deliver drugs for cance...
(Date:11/6/2009)...gistration is now open for the Society of Interven...cology (IO) Therapies" Webinar, which will provide...ter treatment of liver tumors, kidney tumor ablati...nization of physicians, scientists and allied heal...lth through pioneering advances in image-guided th...
(Date:11/6/2009)...ov. 6 Auburn Hills, MI-based Law E... installing its locker system and patent-pending B....S. Department of Health and Human Services, Natio...MD. The locker system will support the NIH,s enti... our nation,s medical research agency. The projec...
Breaking Biology News(10 mins):Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3Society of Interventional Radiology hosts oncology therapies Webinar, offers resources 2CardioFocus Receives CE Mark for Atrial Fibrillation Ablation Catheter 50857 1CardioFocus Receives CE Mark for Atrial Fibrillation Ablation Catheter 50857 2Burnham Institute for Medical Research and Magellan BioScience Group Inc Announce Drug Discovery Collaboration 12905 1Burnham Institute for Medical Research and Magellan BioScience Group Inc Announce Drug Discovery Collaboration 12905 2Burnham Institute for Medical Research and Magellan BioScience Group Inc Announce Drug Discovery Collaboration 12905 3Symon Announces Revolutionary New Application InView Mobile 26amp 3B 238482 3B 50851 1Symon Announces Revolutionary New Application InView Mobile 26amp 3B 238482 3B 50851 2Symon Announces Revolutionary New Application InView Mobile 26amp 3B 238482 3B 50851 3
...n the cell can serve as an advanced tool for mappi...technique in which non-invasive magnetic resonance... results of this research, conducted by Prof. Mich...egulation Department, were published in the resear...Batya Cohen of the Institute,s Molecular Genetics ...
...Hopkins show that stem cell therapy can be used ef...farction, in pigs. In just two months, stem cells ...ted into the animal,s damaged heart restored heart...percent to 75 percent. , The Hopkins findings, fir...ions of the American Heart Association, are to be ...
... relative excavated last year at Petrified Forest ...ries of how and where the dinosaurs arose more tha... Period. , The animal, one of many creatures from...s thought to be an ancestor of the plant-eating or...tops, which roamed the world millions of years lat...
Other Biology News:Novel live reporting system to track cells 2Stem cell therapy successfully treats heart attack in animals 2Agilent Technologies introduces high-capacity human protein removal system for proteomics research 2Agilent Technologies introduces high-capacity human protein removal system for proteomics research 3Agilent Technologies introduces high-capacity human protein removal system for proteomics research 4
(Date:11/6/2009).... 6 ,, 3Q09 Corpor...enza(TM) E.U. Marketing Authorization to Astellas ...commercial readiness activities Expanded manageme...eting; and Director, Commercial Operations Appoin...udit Committee chairman , Upcoming 2009 Mil...
(Date:11/6/2009)...6 Intarcia Therapeutics, Inc. deli...OS® continuous delivery of exenatide) program... Annual Diabetes Technology Meeting in San Francis...in/prnh/20050301/SFTU126LOGO ) ,, Continuous ...wers Plasma Glucose, HbA1c and Reduces Weight in a...
(Date:11/5/2009).... 5 GenVec, Inc. (Nasdaq...r the third quarter ended September 30, 2009. GenV...share) for the three months ended September 30, 20...er share) in the comparable quarter of 2008. For t...net loss was $14.1 million ($0.15 per share), comp...
(Date:11/5/2009)...ewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bullet...cer, President and CEO of Imagenetix, will be pres...CRO Conference on Thursday, December 3rd, at 10:30...bout LD MICRO ,, LD MICRO is a by-invitation on...lued companies in the micro-cap space. Since 2002,...
Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2
...s available for technology companies as part of a ... Standards and Technologys Advanced Technology Pr...ligible for an award, and proposals in all technol...s program are a primary source of R&D capital for ...ve an impact across several industrial and social ...
...ed today it has been chosen again to provide scori...nsin-Madisons Camp Randall Stadium and Kohl Center...uipment provided by the South Dakota-based company...eds $5 million with installation scheduled to be c...ll and 2005 Badger basketball seasons. , ,These in...
...ced today they have signed a distribution agreemen...t distributor of advanced clinical in-vitro diagno...ys distribution agreement announced last Wednesday...oal; to create innovative solutions that provide s...hly skilled team provides specialized diagnostic p...
Other Biology Technology:Daktronics to provide Camp Randall and Kohl Center with scoreboards, display systems 2
...gands\n\nReceptor-related research has long been e...abeled ligands selected to keep pace with new disc...ts and services for receptor research and drug dis...igands. If you do not find exactly what you need, ...
...ve and specific detection of microRNAs (miRNAs) by...ave high binding affinity and discrimination, enab...s. Due to the high binding affinity of the miRCURY... needed compared to traditional probes. Furthermor...
Rabbit Anti-Mouse Vitronectin Polyclonal Antibody, Unconjugated from Abcam
...methylation is an irreversible post translational ...o protein activity. At least three types of PRMT e...ese enzymes have been shown to have essential regu... several fundamental areas. These protein include ...
Biology Products: